Pfizer Licenses eFFECTOR's eIF4E Inhibitors to Bolster Oncology Pipeline
By Neha Madhwani
Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)
Published: 29 Jan-2020
DOI: 10.3833/pdr.v2020.i1.2507 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer has entered into a licensing agreement with eFFECTOR Therapeutics to develop and commercialise translation regulation therapies for the treatment of cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS